An official website of the United States government
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Trial Status: complete
The purpose of this study is to evaluate the safety, tolerability, drug effects, drug
levels and preliminary antitumor activity of BMS-986416 when administered alone and in
combination with Nivolumab in participants with select advanced solid tumors.
Inclusion Criteria
Participants with histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent select solid tumor
Eligible tumor types Non-small cell lung cancer (NSCLC), Urothelial carcinoma (UC), Squamous cell carcinoma of the head and neck (SCCHN), Hepatocellular carcinoma (HCC), Microsatellite-stable colorectal carcinoma (MSS CRC), or Pancreatic ductal adenocarcinoma (PDAC)
Resistant/refractory to or intolerant of existing standard therapies known to provide clinical benefit
Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)
Disease amenable to serial biopsy
Exclusion Criteria
Uncontrolled or significant cardiovascular disease
Known connective tissue disease such as Marfan, Ehlers-Danlos, or Loeys-Dietz syndrome
Medical requirement for chronic anticoagulant or antiplatelet agents (except low-dose aspirin, which is permitted) Other protocol-defined inclusion/exclusion criteria apply
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04943900.
